CA2117480A1 - Immunoglobuline humaine pour la prevention et le traitement des infections a staphylocoques - Google Patents
Immunoglobuline humaine pour la prevention et le traitement des infections a staphylocoquesInfo
- Publication number
- CA2117480A1 CA2117480A1 CA002117480A CA2117480A CA2117480A1 CA 2117480 A1 CA2117480 A1 CA 2117480A1 CA 002117480 A CA002117480 A CA 002117480A CA 2117480 A CA2117480 A CA 2117480A CA 2117480 A1 CA2117480 A1 CA 2117480A1
- Authority
- CA
- Canada
- Prior art keywords
- epidermidis
- immune globulin
- human immune
- directed
- screened
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 81
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 81
- 206010041925 Staphylococcal infections Diseases 0.000 title claims abstract description 4
- 238000011282 treatment Methods 0.000 title claims description 8
- 230000002265 prevention Effects 0.000 title claims description 7
- 241000191963 Staphylococcus epidermidis Species 0.000 claims abstract description 20
- 208000015181 infectious disease Diseases 0.000 claims description 36
- 230000001662 opsonic effect Effects 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 21
- 238000003556 assay Methods 0.000 claims description 20
- 229940028435 intralipid Drugs 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 230000001681 protective effect Effects 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- 238000002965 ELISA Methods 0.000 claims description 13
- 231100000518 lethal Toxicity 0.000 claims description 11
- 230000001665 lethal effect Effects 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000000099 in vitro assay Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000000941 anti-staphylcoccal effect Effects 0.000 claims 2
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 231100000225 lethality Toxicity 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 19
- 208000031729 Bacteremia Diseases 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 206010040047 Sepsis Diseases 0.000 description 16
- 230000036039 immunity Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 10
- 230000001771 impaired effect Effects 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 7
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 235000016236 parenteral nutrition Nutrition 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 101710125089 Bindin Proteins 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000509992 Eremias Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000036364 Normal newborn Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000037412 Sepsis in premature infants Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 150000007854 aminals Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 229940009600 gammagard Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80431792A | 1992-02-25 | 1992-02-25 | |
| US804,317 | 1992-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2117480A1 true CA2117480A1 (fr) | 1993-09-02 |
Family
ID=25188685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002117480A Abandoned CA2117480A1 (fr) | 1992-02-25 | 1992-11-09 | Immunoglobuline humaine pour la prevention et le traitement des infections a staphylocoques |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0628056A4 (fr) |
| JP (1) | JPH08504167A (fr) |
| AU (1) | AU673508B2 (fr) |
| CA (1) | CA2117480A1 (fr) |
| WO (1) | WO1993017044A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0635132B2 (fr) * | 1992-03-19 | 2008-05-14 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Anticorps opsoniques fortement reactifs, reagissant aux antigenes communs des staphylocoques |
| US6933366B2 (en) | 1996-12-27 | 2005-08-23 | Tripep Ab | Specificity exchangers that redirect antibodies to bacterial adhesion receptors |
| US6660842B1 (en) | 1994-04-28 | 2003-12-09 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| JPH0840932A (ja) | 1994-07-29 | 1996-02-13 | Kitasato Inst:The | スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法 |
| US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| US7250494B2 (en) | 1998-06-15 | 2007-07-31 | Biosynexus Incorporated | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
| US6692739B1 (en) | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| US7335359B2 (en) | 2003-02-06 | 2008-02-26 | Tripep Ab | Glycosylated specificity exchangers |
| EP2230249A3 (fr) | 2003-02-06 | 2010-12-22 | ChronTech Pharma AB | Antigène/anticorps ou ligand/récepteur glycosyles avec un échangeur de spécificité |
| WO2007060546A2 (fr) * | 2005-05-31 | 2007-05-31 | Bengt Guss | Caracterisation de proteines de staphylococcus epidermidis portant le motif lpxtg |
| EA016268B1 (ru) * | 2009-05-12 | 2012-03-30 | Государственное Учреждение ''Республиканский Научно-Практический Центр Трансфузиологии И Медицинских Биотехнологий'' | Способ получения антистафилококковой плазмы крови |
| FR2989589A1 (fr) * | 2012-04-20 | 2013-10-25 | Univ Paris Curie | Prevention et traitement des infections non virales chez des individus traites par des immunosuppresseurs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1499035A (en) * | 1975-04-10 | 1978-01-25 | Ts Nii Gematologii I Perelivan | Antistaphylococcus human immune globulin and method of preparing same |
| JPS5452794A (en) * | 1977-09-30 | 1979-04-25 | Kousaku Yoshida | Extracting of polysacchride from capusle containing epidermis staphylococus |
-
1992
- 1992-11-09 JP JP5514800A patent/JPH08504167A/ja active Pending
- 1992-11-09 AU AU32718/93A patent/AU673508B2/en not_active Expired
- 1992-11-09 WO PCT/US1992/009830 patent/WO1993017044A1/fr not_active Application Discontinuation
- 1992-11-09 EP EP93901435A patent/EP0628056A4/fr not_active Withdrawn
- 1992-11-09 CA CA002117480A patent/CA2117480A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0628056A4 (fr) | 1997-03-05 |
| AU673508B2 (en) | 1996-11-14 |
| EP0628056A1 (fr) | 1994-12-14 |
| JPH08504167A (ja) | 1996-05-07 |
| AU3271893A (en) | 1993-09-13 |
| WO1993017044A1 (fr) | 1993-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6632432B1 (en) | Directed human immune globulin for the prevention and treatment of staphylococcal infections | |
| JP4656728B2 (ja) | ブドウ球菌抗原及びワクチン | |
| US5571511A (en) | Broadly reactive opsonic antibodies that react with common staphylococcal antigens | |
| US6294177B1 (en) | Staphylococcus aureus antigen-containing whole cell vaccine | |
| EP0648127B1 (fr) | Antigenes de surface du type i associes au staphylococcus epidermidis | |
| JP2009227680A (ja) | 腸球菌抗原およびワクチン | |
| Hellman et al. | Release of Gram-Negative Outer-Membrane Proteins into Human Serum and Septic Rat Blood and Their Interactions with Iminunoglobulin in Antiserum to Eschevichia coli J5 | |
| CA2117480A1 (fr) | Immunoglobuline humaine pour la prevention et le traitement des infections a staphylocoques | |
| Magnadóttir et al. | A comparison of total and specific immunoglobulin levels in healthy Atlantic salmon (Salmo salar L.) and in salmon naturally infected with Aeromonas salmonicida subsp. achromogenes | |
| CA2132421C (fr) | Anticorps opsoniques largement reactifs qui reagissent avec les antigenes des staphylocoques communs | |
| AT397803B (de) | Humaner monoklonaler antikörper und hybridom zur herstellung desselben | |
| US6391315B1 (en) | Vaccine for inhibiting and preventing induced staphylococcus infection, isolated antigens used therein, and isolated antibodies induced thereby | |
| Matthews et al. | Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum. | |
| US4965068A (en) | Polyvalent hyperimmunoglobulin preparation | |
| CA2257826A1 (fr) | Adhesine d'helicobacter pylori se fixant a un antigene de groupe sanguin | |
| US5034515A (en) | Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use | |
| Loeffler et al. | Use of 51Cr release to measure the cytotoxic effects of staphylococcal leukocidin and toxin neutralization on bovine leukocytes | |
| Dolby et al. | The antibody activities of 19S and 7S fractions from rabbit antisera to Bordetella pertussis | |
| RU2311197C1 (ru) | Способ получения протективной белоксодержащей фракции бактерий | |
| EP0761819A1 (fr) | Exopolysaccharides du burkholderia pseudomallei et burkholderia mallei | |
| CA2200691C (fr) | Anticorps a activite opsonique etendue reagissant avec les antigenes du staphylocoque | |
| Stinson et al. | Binding of Streptococcus mutans antigens to heart and kidney basement membranes | |
| AT395591B (de) | Humaner monoklonaler antikoerper, verfahren zu dessen herstellung, arzneimittel und hybridzelle | |
| WO1996009321A9 (fr) | Anticorps a activite opsonique etendue reagissant avec les antigenes du staphylocoque | |
| EP0450573A2 (fr) | Anticorps pour le traitement et le diagnostic d'infections de Pseudomonas aeruginosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |